Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Cyclophosphamide
Related studies linked through entity extraction aliases.
Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
- Status
- RECRUITING
- Phase
- PHASE1
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
- Status
- RECRUITING
- Phase
- PHASE1
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
- Status
- RECRUITING
- Phase
- PHASE2
Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome
- Status
- RECRUITING
- Phase
- PHASE2
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Allo HSCT Using RIC and PTCy for Hematological Diseases
- Status
- RECRUITING
- Phase
- PHASE2
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
- Status
- UNKNOWN
- Phase
- PHASE1
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- UNKNOWN
- Phase
- NA
Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Post-transplantation Cyclophosphamide in Haploidentical Stem Cell Allografts Dose Reduction: 50 mg/kg vs 25 mg/kg
- Status
- UNKNOWN
- Phase
- NA
R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma
- Status
- UNKNOWN
- Phase
- NA
Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia
- Status
- RECRUITING
- Phase
- PHASE1
Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors
- Status
- RECRUITING
- Phase
- PHASE1
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2